ReviewCells2021
Towards a Functional Cure for Diabetes Using Stem Cell-Derived Beta Cells: Are We There Yet?
Review in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A meta-analysis on application and prospect of cell therapy in the treatment of diabetes mellitus.Stem cell research & therapy · 2025Pooled it
- MLPH/RAB3A accelerates the differentiation of pancreatic stem cells to islet β-cells to control blood glucose in diabetic rats.Organogenesis · 2026Article
- The comparative cell physiology of stem cell-derived and primary human β cells.Nature reviews. Endocrinology · 2026Review
- Insulin gene-modified 3D stem cells for enhanced islet regeneration and systemic reversal of type 1 diabetes.Stem cells translational medicine · 2026Article
- Transient ER stress cell-autonomously promotes beta cell cycling in mice.Diabetologia · 2026Article
- Assessing mesh size and diffusion of alginate bioinks: A crucial factor for successful bioprinting functional pancreatic islets.Materials today. Bio · 2025Article
- Stem cell-derived pancreatic beta cells: a step closer to functional diabetes treatment?BMC endocrine disorders · 2025Review
- Evaluation of the in vivo antidiabetic, in vitro antioxidant and alpha amylase inhibitory effects of Ocimum lamiifolium Hochst ex Benth leaf hydromethanolic crude extract in streptozotocin-induced diabetic mouse model.BMC complementary medicine and therapies · 2025Article
- Immunomodulatory agents and cell therapy for patients with type 1 diabetes.Archives of endocrinology and metabolism · 2025Review
- Extracellular matrix proteins refine microenvironments for pancreatic organogenesis from induced pluripotent stem cell differentiation.Theranostics · 2025Article
- Medical embryology and regenerative medicine: research and applications in clinical practice.Frontiers in cell and developmental biology · 2025Review
- Electrophysiological Characterization of Inducible Pluripotent Stem Cell-Derived Human β-Like Cells and an SLC30A8 Disease Model.Diabetes · 2024Article
- Integrating population genetics, stem cell biology and cellular genomics to study complex human diseases.Nature genetics · 2024Article
- Analysis of beta-cell maturity and mitochondrial morphology in juvenile non-human primates exposed to maternal Western-style diet during development.Frontiers in endocrinology · 2024Article
- Advanced therapy to cure diabetes: mission impossible is now possible?Frontiers in cell and developmental biology · 2024Review
- Electrophysiological characterisation of iPSC-derived human β-like cells and anbioRxiv : the preprint server for biology · 2023Article
- Article
- The Evolution of Diabetes Treatment Through the Ages: From Starvation Diets to Insulin, Incretins, SGLT2-Inhibitors and Beyond.Journal of the Indian Institute of Science · 2023Review
- Understanding Insulin in the Age of Precision Medicine and Big Data: Under-Explored Nature of Genomics.Biomolecules · 2023Review
- Benefits and Hurdles of Pancreatic β-Cell Replacement.Stem cells translational medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus is a pandemic metabolic disorder that results from either the autoimmune destruction or the dysfunction of insulin-producing pancreatic beta cells. A promising cure is beta cell replacement through the transplantation of islets of Langerhans. However, donor shortage hinders the widespread implementation of this therapy. Human pluripotent stem cells, including embryonic stem cells and induced pluripotent stem cells, represent an attractive alternative beta cell source for transplantation. Although major advances over the past two decades have led to the generation of stem cell-derived beta-like cells that share many features with genuine beta cells, producing fully mature beta cells remains challenging. Here, we review the current status of beta cell differentiation protocols and highlight specific challenges that are associated with producing mature beta cells. We address the challenges and opportunities that are offered by monogenic forms of diabetes. Finally, we discuss the remaining hurdles for clinical application of stem cell-derived beta cells and the status of ongoing clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.